{"nctId":"NCT01301833","briefTitle":"Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes","startDateStruct":{"date":"2011-02"},"conditions":["Type 2 Diabetes Mellitus"],"count":462,"armGroups":[{"label":"teneligliptin","type":"EXPERIMENTAL","interventionNames":["Drug: teneligliptin"]},{"label":"teneligliptin and glinide","type":"EXPERIMENTAL","interventionNames":["Drug: teneligliptin","Drug: glinide"]},{"label":"teneligliptin and biguanide","type":"EXPERIMENTAL","interventionNames":["Drug: teneligliptin","Drug: biguanide"]},{"label":"teneligliptin and alpha-glucosidase inhibitor","type":"EXPERIMENTAL","interventionNames":["Drug: teneligliptin","Drug: alpha-glucosidase inhibitor"]}],"interventions":[{"name":"teneligliptin","otherNames":["MP-513"]},{"name":"glinide","otherNames":[]},{"name":"biguanide","otherNames":[]},{"name":"alpha-glucosidase inhibitor","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who has been receiving a stable dose and regimen of oral antihyperglycaemic agent (biguanide agent,Î±-glucosidase inhibitor,rapid insulin secretagogue) for diabetes over 12 weeks before administration of investigational drug\n* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug\n* Patients whose HbA1c is between 6.5% - 10.0%\n* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)\n* Patients who are accepting treatments of arrhythmias\n* Patients with serious diabetic complications\n* Patients who are habitual excessive alcohol consumption.\n* Patients with severe hepatic disorder or severe renal disorder.\n* Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"Treatment-emergent adverse events (TEAE) were defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after receiving the last dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"182","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"81","spread":null},{"groupId":"OG003","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c at Week 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.63","spread":"0.64"},{"groupId":"OG001","value":"-0.76","spread":"0.70"},{"groupId":"OG002","value":"-0.78","spread":"0.75"},{"groupId":"OG003","value":"-0.89","spread":"0.64"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose at Week 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.7","spread":"25.5"},{"groupId":"OG001","value":"-13.7","spread":"23.7"},{"groupId":"OG002","value":"-12.7","spread":"27.1"},{"groupId":"OG003","value":"-19.5","spread":"23.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Glucagon at Week 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"12.5"},{"groupId":"OG001","value":"5.3","spread":"13.7"},{"groupId":"OG002","value":"5.0","spread":"14.4"},{"groupId":"OG003","value":"6.9","spread":"15.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Immuno Reactive Insulin (IRI) at Week 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.988","spread":"8.314"},{"groupId":"OG001","value":"0.211","spread":"2.378"},{"groupId":"OG002","value":"-0.173","spread":"9.093"},{"groupId":"OG003","value":"-0.330","spread":"2.713"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":212},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Blood urine present","Protein urine present","Blood creatine phosphokinase increased"]}}}